ALX Oncology: CMO Alan Sandler resigns, Barbara Klencke appointed Interim CMO; Nasdaq compliance regained

ALX ONCOLOGY HOLDINGS INC

Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.
Barbara Klencke steps down from Board to become Interim CMO effective Sep 17, 2025.
ALX regained Nasdaq minimum bid price compliance (closing bid >= $1 for 10 consecutive days through Sep 4, 2025).
Board committee changes: R&D committee paused; new Audit, Compensation, and Governance committee assignments approved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.